サポート ブログ How Therapeutic Antibodies Are Produced: Screening and Selection

How Therapeutic Antibodies Are Produced: Screening and Selection

Biointron 2024-02-23 Read time: 5 mins
Bioengineering.jpg
Image credit: DOI: 10.3390/bioengineering8020030

Once potential therapeutic antibodies are engineered, they undergo rigorous screening and selection to identify the most promising candidates.

Screening Methods

Traditionally, screening for potential therapeutic antibodies includes enzyme-linked immunosorbent assay (ELISA), a versatile tool measuring the binding affinity of antibodies to their target antigens. This provides valuable insights into the strength of their interaction. Surface plasmon resonance (SPR) takes it a step further by monitoring the real-time binding kinetics, offering crucial information about the speed and stability of the antibody-antigen interaction. Cell-based assays bridge the gap by assessing the antibodies' biological activity in living cells, mimicking their real-world action against diseased cells or pathogens. Examples include cytotoxicity assays that evaluate cell-killing abilities and assays that measure immune cell activation. Finally, flow cytometry allows researchers to differentiate and analyze cell populations, enabling them to assess the impact of antibodies on specific cell types within a complex mixture.1

While these methods are invaluable, their traditional approach can be time-consuming and labor-intensive, especially when dealing with vast antibody libraries containing millions of potential candidates. This is where high-throughput screening (HTS) emerges by automating and miniaturizing screening processes. HTS allows researchers to test thousands of antibody variants simultaneously, significantly accelerating the identification of promising candidates. Examples of HTS technologies employed in antibody screening include:

  • Phage display: Millions of antibody-presenting bacteriophages can be screened against immobilized antigens, rapidly identifying binders with desired characteristics. 

  • Microfluidic platforms: Miniaturized channels enable testing many antibody samples simultaneously with minimal reagent volumes, optimizing efficiency and speed.

  • Bead-based assays: Antibodies are coupled to beads and exposed to various targets, allowing for multiplexed analysis and fast identification of specific binders, streamlining the selection process.2

Often, a combination of techniques is employed, with HTS guiding the initial selection and traditional methods providing in-depth characterization of promising candidates. As the field of antibody screening continues to evolve, innovative technologies like machine learning and artificial intelligence (AI) are being integrated to predict antibody properties and personalize screening strategies. This continuous advancement promises even more efficient and effective identification of next-generation therapeutic antibodies, ultimately translating into more targeted and successful treatments for various diseases.3

Criteria for Selection

  • Specificity and Affinity: The antibody must exhibit high specificity for the target antigen and a strong binding affinity to ensure effective targeting and therapeutic action. However, for some therapeutic strategies, targeting broader categories of related antigens might be necessary for efficacy, requiring some flexibility in this criterion.

  • Efficacy: Antibodies must demonstrate the ability to elicit the desired biological response, such as inhibiting disease-causing molecules or marking diseased cells for destruction by the immune system.

  • Safety: Selected antibodies must show a low potential for adverse effects, such as triggering immune responses or cross-reactivity with non-target tissues.

  • Developability: Considerations include the antibody's stability, solubility, and manufacturability on a large scale without losing its functional properties.

The screening and selection phase narrows down the vast pool of engineered antibodies to the most promising candidates that combine high therapeutic potential with safety and manufacturability. As the field of antibody engineering continues to evolve, new selection strategies and sophisticated tools will undoubtedly emerge, further refining the process and paving the way for even more effective and targeted antibody-based therapies.

Biointron can help in your therapeutic antibody production. We provide services for HTP Recombinant Antibody Production, Bispecific Antibody Production, Large Scale Antibody Production, Afucosylated Antibody Expression, and RushMab™ - Small Scale Expression Packages. Learn more here: https://www.biointron.com/services/.


References:

  1. Makowski, E. K., Wu, L., Gupta, P., & Tessier, P. M. (2021). Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods. MAbs, 13(1). https://doi.org/10.1080/19420862.2021.1895540

  2. Sun, H., Hu, N., & Wang, J. (2022). Application of microfluidic technology in antibody screening. Biotechnology Journal, 17(8), 2100623. https://doi.org/10.1002/biot.202100623

  3. Kim, J., McFee, M., Fang, Q., Abdin, O., Kim, P. M. (2023). Computational and artificial intelligence-based methods for antibody development. Trends in Pharmacological Sciences, 14(3). https://doi.org/10.1016/j.tips.2022.12.005

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。